Clinical Trial Update: MK-2206 in Recurrent Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of MK-2206 in recurrent nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Recurrent Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED